San Diego-based Tandem revealed that it received FDA approval for the Android version of its Mobi mobile app. Clearance brings Mobi — which the company describes as the world’s smallest, durable automated insulin delivery system — to more users. The pump, which pairs with Tandem’s Control-IQ+ algorithm, previously worked with iOS software.
Tandem — one of the largest diabetes tech companies in the world — expects to begin a limited rollout next month, followed by full commercial availability in early 2026. This marks the latest milestone for the company, which continues to expand its offerings and widen its reach within the diabetes patient population.
The company began the year by launching the next-generation Congrol-IQ+ algorithm earlier this year. It followed that up by announcing the future pairing of Tandem systems with Abbott’s under-development dual glucose-ketone sensor and kicking off the launch of its t:slim X2 pump with the Abbott FreeStyle Libre 3 Plus last month.
Now, with the latest FDA clearance in hand, the company believes it can bring its insulin delivery technology to even more people.
Our sister site, Drug Delivery Business News spoke with Tandem Director of Product Marketing Ben Mar to understand the significance of the FDA clearance and discuss the plans for the company down the road.
